Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Modern Pathology

Volumn 29, Issue 10, 2016, Pages 1165-1172

  Scheel, Andreas H ^a   Dietel, Manfred ^b   Heukamp, Lukas C ^c   Jöhrens, Korinna ^b   Kirchner, Thomas ^d   Reu, Simone ^d   Rüschoff, Josef ^e   Schildhaus, Hans Ulrich ^f   Schirmacher, Peter ^g   Tiemann, Markus ^c   Warth, Arne ^g   Weichert, Wilko ^h   Fischer, Rieke N ^a   Wolf, Jürgen ^a   Buettner, Reinhard ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Institute of Hematopathology Hamburg   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Institute of Pathology Nordhessen   (Germany)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER SURGERY; CARCINOMA CELL; CELL ASSAY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG RESECTION; PATHOLOGIST; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; SQUAMOUS CELL LUNG CARCINOMA; STAINING; STANDARDIZATION; TISSUE SECTION; ADENOCARCINOMA; LUNG TUMOR; OBSERVER VARIATION; PROCEDURES; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; OBSERVER VARIATION;

EID: 84978176895     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.117     Document Type: Article

References (18)

1. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
2. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
3. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387: 1540-1550.
4. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846.
5. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
6. Kerr KM, Tsao M-S, Nicholson AG et al. PD-L1 immunohistochemistry in lung cancer: in what state is this art?. J Thorac Oncol 2015;10:985-989.
7. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-2012.
8. Garon EB, Rizvi NA, Hui R. KEYNOTE-001 investigators: pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
9. Herbst RS, Soria JC, Kowanetz M et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515: 563-567.
10. Seidel D, Zander T, Heukamp LC et al. A genomicsbased classification of human lung tumors. Sci Transl Med 2013;5:209ra153.
11. Koh J, Go H, Keam B et al. Clinicopathologic analysis of programmed cell death-1 and programmed cell deathligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status. Mod Pathol 2015;28:1154-1166.
12. Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther 2005;85:257-268.
13. Bhargava R, Dabbs DJ. Immunhistology of the breast, theranostic applications. In: Dabbs DJ (ed). Diagnostic Immunohistochemistry: Theranostic and Genomic Applications, 4th edn. Elsevier Saunders: Philadelphia, PA, USA, 2014, pp 744-750.
14. Rüschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
15. Von Laffert M, Warth A, Penzel R et al. Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J Thorac Oncol 2014;9:1685-1692.
16. Rüschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-650.
17. Robert C, Schachter J, Long GV. KEYNOTE-006 investigators: pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-2532.
18. McDermott DF, Drake CG, Sznol M et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015;33:2013-2020.